Online Database of Chemicals from Around the World

Palmitoylethanolamide
[CAS# 544-31-0]

List of Suppliers
Hefei TNJ Chemical Industry Co., Ltd. China Inquire
www.tnjchem.com
+86 (551) 6541-8684
+86 (551) 6541-8697
sales@tnjchem.com
Chemical manufacturer since 2001
chemBlink Standard supplier since 2010
BOC Sciences USA Inquire
www.bocsci.com
+1 (631) 485-4226
+1 (631) 614-7828
info@bocsci.com
Chemical manufacturer
chemBlink Standard supplier since 2010
Intatrade Chemicals GmbH Germany Inquire
www.intatrade.de
+49 (3493) 605-465
+49 (3493) 605-470
sales@intatrade.de
Chemical distributor
chemBlink Standard supplier since 2011
Gihi Chemicals Co., Ltd. China Inquire
www.gihichem.com
+86 (571) 8621-7390
+86 18072806364
+86 (571) 8621-7391
sales@gihichem.com
Chemical manufacturer since 2000
chemBlink Standard supplier since 2013
Suzhou Myland Pharm & Nutrition Inc. China Inquire
www.mylandpharm.com
+86 (512) 6615-0687
+86 (512) 6615-7101
info@mylandpharm.com
QQ Chat
Chemical manufacturer since 2013
chemBlink Standard supplier since 2014
Hangzhou Leap Chem Co., Ltd. China Inquire
www.leapchem.com
+86 (571) 8771-1850
market19@leapchem.com
QQ Chat
Chemical manufacturer since 2006
chemBlink Standard supplier since 2015
Beijing Leaderherb Bio-tech. Co., Ltd. China Inquire
www.china-api.cn
+86 (10) 5128-8246
+86 (10) 5649-5849
300abc@sina.com
Chemical manufacturer since 2006
chemBlink Standard supplier since 2016
Hangzhou Hairui Chemical Co., Ltd. China Inquire
www.hairuichem.com
+86 (571) 8669-1155
+86 (571) 8669-1154
sales@hairuichem.com
Chemical distributor since 2005
chemBlink Standard supplier since 2017
Papchem Lifesciences India Inquire
papchemlifesciences.com
9061328401
bd@papchemlifesciences.com
Chemical manufacturer since 2021
chemBlink Standard supplier since 2024
Natural Micron Pharm Tech Co., Ltd. China Inquire
nmpharmtech.com
+86 (0538) 535-2278
info@nmpharmtech.com
Chemical manufacturer since 2012
chemBlink Standard supplier since 2025
Santa Cruz Biotechnology, Inc. USA Inquire
www.scbt.com
+1 (831) 457-3800
+1 (831) 457-3801
scbt@scbt.com
Chemical manufacturer
AK Scientific, Inc USA Inquire
www.aksci.com
+1 (510) 429-8835
+1 (510) 429-8836
sales@aksci.com
Chemical manufacturer

Identification
ClassificationBiochemical >> Inhibitor >> DNA damage >> PPAR inhibitor
NamePalmitoylethanolamide
SynonymsN-(2-Hydroxyethyl)hexadecanamide; PEA; Palmidrol
Molecular StructureCAS # 544-31-0, Palmitoylethanolamide
Molecular FormulaC18H37NO2
Molecular Weight299.49
Protein SequenceG
CAS Registry Number544-31-0
EC Number208-867-9
SMILESCCCCCCCCCCCCCCCC(=O)NCCO
Properties
Solubility20 mM (DMSO), 25 mM (ethanol)
Melting point98-99 °C
Safety Data
Hazard Symbolssymbol symbol symbol   GHS05;GHS07;GHS09 Danger  Details
Risk StatementsH315-H318-H411-H412  Details
Safety StatementsP264-P264+P265-P273-P280-P302+P352-P305+P354+P338-P317-P321-P332+P317-P362+P364-P391-P501  Details
Hazard Classification
up    Details
HazardClassCategory CodeHazard Statement
Chronic hazardous to the aquatic environmentAquatic Chronic3H412
Serious eye damageEye Dam.1H318
Skin irritationSkin Irrit.2H315
SDSAvailable
up Discovery and Applications
Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide with important biological and therapeutic significance. PEA is well known for its role in the endocannabinoid system and has attracted much attention for its health benefits and applications.

Palmitoylethanolamide, with the molecular formula C18H37NO2, was first discovered in the 1950s as a component of soybeans. It is a member of the N-acylethanolamine family, which also includes other compounds such as anandamide. PEA was discovered while studying biochemical pathways involved in inflammation and pain.

PEA is a fatty acid amide derived from palmitic acid and ethanolamine. It is a white, odorless powder that is soluble in organic solvents but poorly soluble in water. Its chemical structure is characterized by long-chain fatty acids esterified with ethanolamine groups, which contribute to its biological activity.

Palmitoylethanolamide has been widely studied for its anti-inflammatory and analgesic properties. It is believed to modulate pain and inflammation by affecting the endocannabinoid system and interacting with various receptors. Clinical studies have shown that PEA is effective in managing chronic pain conditions, including neuropathic pain and inflammatory diseases.

Research suggests that PEA may have neuroprotective effects. It is believed to support neuronal health and prevent neurodegenerative diseases by reducing inflammation and oxidative stress. Its potential use in treating diseases such as multiple sclerosis and Alzheimer's disease is being investigated.

PEA's anti-inflammatory properties extend to allergic diseases. It has shown promise in reducing symptoms of allergic rhinitis and asthma by modulating inflammatory responses, making it a candidate for developing new treatments for allergic diseases.

In dermatology, PEA is being explored for its potential to improve skin health. Its anti-inflammatory effects are beneficial in treating conditions such as eczema and psoriasis. Topical formulations of PEA are being developed to soothe symptoms of skin diseases.

Due to its wide range of potential health benefits, PEA is available as a dietary supplement. It plays an important role in supporting overall health, including pain relief, cognitive function, and immune health.

As a natural compound, PEA is considered to have a good safety profile and minimal side effects compared to synthetic drugs. PEA's ability to affect a variety of biological pathways gives it the flexibility to treat a wide range of conditions, from pain and inflammation to neurological and allergic diseases. Ongoing research continues to reveal new therapeutic potential for PEA, enhancing its applicability in modern medicine and complementary health practices.

References

2020. URB597 Prevents the Short-Term Excitotoxic Cell Damage in Rat Cortical Slices: Role of Cannabinoid 1 Receptors. Neurotoxicity Research, 38(4).
DOI: 10.1007/s12640-020-00301-1

2018. Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial. Clinical Oral Investigations, 23(4).
DOI: 10.1007/s00784-018-2720-7

2013. N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress. Pharmacological Research, 76.
DOI: 10.1016/j.phrs.2013.07.007
Market Analysis Reports
List of Reports Available for Palmitoylethanolamide
Related Products
N(4)-Palmitoyl ...  N-Palmitoyldaun...  1-Palmitoyl-2-o...  N-Palmitoyl-DL-...  Palmitoyl Dihyd...  N-Palmitoyl-5,6...  1-Palmitoyl-2-D...  1-Palmitoyl-2-(...  Palmitoyleicosa...  1-Palmitoyl-2-(...  Palmitoyl-(1,N(...  5'-O-Palmitoyl-...  3-O-Palmitoyl-b...  3-O-(6'-O-Palmi...  Palmitoyl Gluta...  N-Palmitoylglut...  Palmitoylhomocy...  12-O-Palmitoyl-...  rac-1-Palmitoyl...  rac-1-Palmitoyl...